for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Haemonetics Corporation

HAE.N

Latest Trade

129.44USD

Change

0.91(+0.71%)

Volume

562,104

Today's Range

128.73

 - 

131.54

52 Week Range

80.25

 - 

140.22

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
128.53
Open
128.73
Volume
562,104
3M AVG Volume
7.69
Today's High
131.54
Today's Low
128.73
52 Week High
140.22
52 Week Low
80.25
Shares Out (MIL)
50.77
Market Cap (MIL)
6,525.45
Forward P/E
41.94
Dividend (Yield %)
--

Next Event

Q2 2020 Haemonetics Corp Earnings Release

Latest Developments

More

Haemonetics Corp Reports Financial Results For Its First Quarter Of Fiscal 2020

Haemonetics To Transfer Union, South Carolina, Manufacturing Facility To Csl Plasma Inc.

Haemonetics Corp Sees Fy20 HAE Reported Revenue Up 3‐5% Assuming Close Of CSL Deal

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Industry

Medical Equipment & Supplies

Contact Info

400 WOOD RD

+1.781.8487100

https://www.haemonetics.com

Executive Leadership

Richard J. Meelia

Non-Executive Independent Chairman of the Board

Christopher Simon

President, Chief Executive Officer, Director

William P. Burke

Chief Financial Officer, Executive Vice President

Said Bolorforosh

Executive Vice President, Chief Technology Officer

Michelle L. Basil

Executive Vice President, General Counsel

Key Stats

2.00 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.9K

2018

0.9K

2019

1.0K

2020(E)

1.0K
EPS (USD)

2017

1.530

2018

1.870

2019

2.390

2020(E)

3.065
Price To Earnings (TTM)
138.02
Price To Sales (TTM)
6.68
Price To Book (MRQ)
11.04
Price To Cash Flow (TTM)
40.84
Total Debt To Equity (MRQ)
73.73
LT Debt To Equity (MRQ)
53.83
Return on Investment (TTM)
4.90
Return on Equity (TTM)
3.95

Latest News

BRIEF-Haemonetics Reports Qtrly Earnings Per Share Of $0.22

* SEES FISCAL 2019 TOTAL REVENUE GROWTH 3 PERCENT TO 5 PERCENT

BRIEF-Haemonetics Announces Regulatory Clearances

* HAEMONETICS ANNOUNCES REGULATORY CLEARANCES OF NEXSYS PCS™ ENHANCED SOFTWARE WITH YES™ TECHNOLOGY Source text for Eikon: Further company coverage:

BRIEF-Haemonetics Corp Qtrly Revenue $234.0 Million

* QTRLY ADJUSTED EARNINGS PER SHARE $0.62; QTRLY LOSS PER SHARE $0.12

BRIEF-Haemonetics appoints David Wilson plasma business unit president

* Haemonetics appoints David Wilson plasma business unit president Source text for Eikon: Further company coverage:

BRIEF-Haemonetics Corp reports Q1 earnings per share $0.38

* Qtrly earnings per share $0.38; Qtrly adjusted earnings per share $0.33

BRIEF-Haemonetics announces FDA clearance of new plasmapheresis system branded nexsys PCS

* Haemonetics announces FDA clearance of new plasmapheresis system branded Nexsys pcs Source text for Eikon: Further company coverage:

BRIEF-Haemonetics Corp reports qtrly loss per share $0.98

* Haemonetics Corp- fourth quarter fiscal 2017 revenue of $228.1 million, down 6pct compared to the fourth quarter of fiscal 2016

BRIEF-Haemonetics reports Q3 EPS $0.30

* Reported Q3 fiscal 2017 revenue of $227.8 million, down 2 pct

BRIEF-Haemonetics Q2 earnings $0.38/shr

* Q2 2017 revenue of $220.3 million, flat with the second quarter of fiscal 2016 as reported, and up 1 percent in constant currency

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up